Literature DB >> 22925318

Bronchial inflammation and hyperresponsiveness in well controlled asthma.

X Muñoz1, S Sanchez-Vidaurre, O Roca, F Torres, F Morell, M J Cruz.   

Abstract

BACKGROUND: Little research has been devoted to the characteristics of bronchial inflammation in patients with stable, well controlled asthma.
OBJECTIVE: The aim of this study was to assess the degree and type of airway inflammation and to investigate the relationship between inflammation and bronchial hyperresponsiveness in patients with well controlled asthma.
METHODS: A cross-sectional study was conducted in 84 adult patients (43 men, mean age 43 years) with documented well controlled asthma. Induced sputum samples were obtained and cell types determined by differential cell count. Spirometry and methacholine challenge testing were performed. Asthma Control Questionnaire (ACQ) was used to assess symptoms. Patients were included if their ACQ score was < 0.75.
RESULTS: A total of 59 patients had persistent bronchial inflammation: 28 cases were considered eosinophilic, 28 neutrophilic, and 3 mixed. Median (range) percentage of eosinophils was 4% (0-64) in patients testing positive to methacholine challenge (n = 66) and 1% (0-3) in those testing negative (n = 18) (P = 0.003). A positive correlation was found between eosinophil percentage and the methacholine dose/response ratio (r = 0.477, P = 0.0001). The geometric mean (95% CI) of the methacholine PC20 was 1.74 mg/mL (1.04-2.93) in patients with eosinophilic inflammation and 4.14 mg/mL (2.5-6.84) in those with neutrophilic inflammation (P = 0.03).
CONCLUSIONS: Inflammation and bronchial hyperresponsiveness persist in most patients with well controlled asthma. CLINICAL RELEVANCE: The study demonstrates that eosinophilic or neutrophilic inflammation persisted in most well controlled asthma patients despite the fact that their condition was controlled and therefore, measurement of bronchial inflammation seems essential to achieve proper asthma control.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925318     DOI: 10.1111/j.1365-2222.2012.04004.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  3 in total

Review 1.  Biomarkers in the Management of Difficult Asthma.

Authors:  Florence Schleich; Sophie Demarche; Renaud Louis
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

2.  Serum BPI as a novel biomarker in asthma.

Authors:  Chen Xingyuan; Qiu Chen
Journal:  Allergy Asthma Clin Immunol       Date:  2020-06-18       Impact factor: 3.406

3.  IL-35 inhibits cell pyroptosis and attenuates cell injury in TNF-α-induced bronchial epithelial cells via p38 MAPK signaling pathway.

Authors:  Yanbo Wang; Yanling Yu; Wanjing Yu; Xun Bian; Linxia Gong
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.